查找地点
有关时间、上门服务和预约查找地点
有关时间、上门服务和预约If the patient's hematocrit exceeds 55%, the volume of citrate in the collection tube must be adjusted. Refer to Coagulation Collection Procedures for directions.
2 - 3 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
Procedures for Hemostasis and Thrombosis: A Clinical Test Compendium
Plasma, frozen
2 mL
1 mL
Blue-top (sodium citrate) tube
Citrated plasma samples should be collected by double centrifugation. Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate.1 Evacuated collection tubes must be filled to completion to ensure a proper blood to anticoagulant ratio.2,3 The sample should be mixed immediately by gentle inversion at least six times to ensure adequate mixing of the anticoagulant with the blood. A discard tube is not required prior to collection of coagulation samples, except when using a winged blood collection device (ie, "butterfly"), in which case a discard tube should be used.4,5 When noncitrate tubes are collected for other tests, collect sterile and nonadditive (red-top) tubes prior to citrate (blue-top) tubes. Any tube containing an alternate anticoagulant should be collected after the blue-top tube. Gel-barrier tubes and serum tubes with clot initiators should also be collected after the citrate tubes. Centrifuge for 10 minutes and carefully remove 2/3 of the plasma using a plastic transfer pipette, being careful not to disturb the cells. Deliver to a plastic transport tube, cap, and recentrifuge for 10 minutes. Use a second plastic pipette to remove the plasma, staying clear of the platelets at the bottom of the tube. Transfer the plasma into a Labcorp PP transpak frozen purple tube with screw cap (Labcorp No. 49482). Freeze immediately and maintain frozen until tested.
Please print and use the Volume Guide for Coagulation Testing to ensure proper draw volume.
Freeze.
Ideally, the patient should not be on anticoagulant therapy. Avoid warfarin (Coumadin®) therapy for two weeks prior to the test and heparin, direct Xa, and thrombin inhibitor therapies for about three days prior to testing.
Severe hemolysis; improper labeling; clotted specimen; specimen diluted with IV fluids; samples thawed in transit; improper sample type; sample out of stability
Distinguish between circulating inhibitor and coagulation factor deficiency when PT is prolonged
Prothrombin time assay
A mixing study is used to study the cause of a prolonged screening test. This study can determine if the cause is a deficiency of one or more factors or an inhibitor.6 In a mixing study, platelet-free, normal plasma that is replete with all coagulation factors (near 100% activity for each) is mixed with the patient sample. For example, in a 1:1 mix, one part patient sample is mixed with one part normal plasma and the mixture is tested. In this case, the lowest possible concentration for any individual factor in the mixture would be approximately 50% (in the case of a patient with a factor concentration of zero) and the normal pool has an activity of 100%. In the absence of inhibitors, this mixture will produce a normal clotting time. When addition of normal plasma fails to correct the clotting time into the normal range, the cause of the abnormal test is likely an inhibitor. The performance and interpretation of mixing studies is described in more detail in the online Coagulation Appendices: Abnormal Screening Results and Lupus Anticoagulants.
Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
---|---|---|---|---|---|---|
117028 | PT Mixing Study | 117030 | PT | sec | 5902-2 | |
117028 | PT Mixing Study | 117031 | PT 1:1NP | sec | 5959-2 | |
117028 | PT Mixing Study | 117032 | 1 Hr Incub PT 1:1NP | sec | 33356-7 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf